Sign In

Asya Grinberg

VP of Biologics Therapeutics

Asya Grinberg is a distinguished leader in biologics drug discovery and early development with a rich history of 20 years in the industry.

She excels in team leadership, forming strategic partnerships, and translating innovative scientific concepts into reality, focusing on clear goal-setting and effective communication to achieve outstanding outcomes.

Notable contributions to the field include involvement in the development of Reblozyl® and Sotatercept, along with multiple clinical assets and preclinical candidates across various stages of development.

Her expertise spans protein engineering, biologics generation, biology, analytical development, CMC, QC, and QA, all geared towards enhancing company value.

Having held key positions at renowned organizations like AstraZeneca, Dragonfly Therapeutics, and Acceleron Pharma, Asya's journey reflects a commitment to excellence and continuous learning.

She holds a Master's degree in Bioorganic Chemistry from Lomonosov Moscow State University and has studied at Universitaet des Saarlandes in Germany, showcasing a strong academic foundation.

As an advocate for innovation, Asya's portfolio boasts over 100 patents and scientific publications, establishing her as a thought leader in the industry.

Her approach emphasizes building a culture of creativity, empowerment, collaboration, and open communication, underpinned by values like honesty, integrity, and courage to explore new horizons.

Asya Grinberg
Add to my network

Location

Cambridge, Massachusetts, United States